The rise of vaccine manufacturers in emerging markets, particularly India, has helped depress the cost of immunization in recent years. Indian suppliers have rolled out vaccines at significant discounts and Western manufacturers have followed suit, slashing prices in poorer countries.
Covance is counting on Asia for an explosion in drug development, and the company has expanded its core lab capacity by 50% in Singapore to serve the growing market for clinical testing in the region.
U.S. preclinical CRO Absorption Systems has signed a deal with Indian consulting firm Synerzys Lifecare, looking to pitch its testing services to the nation's growing generics market.
InVentiv Health is betting on a big expansion in Japanese R&D, forming a strategic alliance with local CRO Bell Medical Solutions to offer lab services in the country.
When it comes to its investment in Japan's Chugai Pharmaceutical, Roche CEO Severin Schwan says he likes things just the way they are
Life Technologies is fielding buyout offers from a competitor and a group of private equity giants, but that hasn't stopped the company from making acquisitions of its own, now snatching up a Korean distributor of reagents and lab instruments.
China revamped, renamed and promoted its drug regulator recently after a series of embarrassing disclosures last year by Chinese media about toxic capsules and cooking oil used in antibiotics. But no sooner had the new ministerial-level agency made its debut then state TV in China reported a new scandal that affected one of its larger drugmakers.
India is proceeding with its plan to reform how sponsors and CROs pay compensation to patients, but the draft guidance contains some confusing wording that has troubled the industry.
India's Supreme Court is keeping the pressure on Western drugmakers. Just days after invalidating a patent for Novartis' cancer drug Glivec, it has said a generic drugmaker there is free, for now, to proceed with its cheap knockoff of Merck's vaunted diabetes drugs.
Pfizer CEO Ian Read has given yet another glimpse into the future of the drugmaker as he shapes it into a more efficient pharmaceutical operation. In a disappointing disclosure to those who look for more spinoffs, he said Pfizer will hold onto its consumer health business.